×

FDA votes on muscular dystrophy drug

7:46 AM ET Mon, 25 April 2016

Sarepta Therapeutics's Eteplirsen is in front of the FDA advisory committee today for a vote on whether the drug is effective in treating Duchenne muscular dystrophy, reports CNBC's Meg Tirrell.